Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Involvement of adiponectin in early stage of colorectal carcinogenesis

Authors: Chung Hyun Tae, Seong-Eun Kim, Sung-Ae Jung, Yang-Hee Joo, Ki-Nam Shim, Hye-Kyung Jung, Tae Hun Kim, Min-Sun Cho, Kwang Ho Kim, Joung Sook Kim

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Although altered levels of adiponectin have been reported as a potential risk factor in colorectal cancer (CRC), the importance of the role played by adiponectin in colorectal carcinogenesis has not been established. We sought to examine the expression pattern of adiponectin and adiponectin receptors (AdipoRs) in the normal-adenoma-carcinoma sequence and to assess the implications of adiponectin in colorectal carcinogenesis.

Methods

Serum adiponectin concentrations, and the mRNA and protein expression of adiponectin and AdipoRs were examined using serum and tissues from patients with CRC, advanced adenoma, and a normal colon. mRNA expression of AdipoRs and epithelial-mesenchymal transition regulators including E-cadherin, cyclooxygenase-2 (COX-2) and T-cadherin were examined in HCT116 cells treated with adiponectin.

Results

Serum adiponectin concentrations in patients with advanced adenoma and CRC were lower than those in controls. Adiponectin mRNA was not detected in colonic tissue, whereas AdipoRs mRNA was lower in advanced adenoma and CRC than that in normal colon tissues. Immunohistochemical staining demonstrated that adiponectin was expressed in spindle-shaped cells of the subepithelial layer in normal colon tissues, whereas ill-defined overexpression of adiponectin was seen in the stroma of advanced adenoma and CRC tissues. AdipoRs expression was strong in normal epithelium, but weak to negative in the epithelia of CRC tissues. Adiponectin downregulated COX-2 mRNA expression in vitro, but upregulated T-cadherin in HCT116 cells.

Conclusions

Systemic adiponectin and local AdipoRs expression in the colon may be associated with anti-tumorigenesis during the early stages of CRC. These findings offer new insight into understanding the relationship between adiponectin and colorectal carcinogenesis.
Appendix
Available only for authorised users
Literature
1.
Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2007, 92 (03): 347-CrossRef
2.
Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996, 221 (2): 286-289. 10.1006/bbrc.1996.0587.CrossRefPubMed
3.
Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996, 271 (18): 10697-10703. 10.1074/jbc.271.18.10697.CrossRefPubMed
4.
Goldfine AB, Kahn CR: Adiponectin: linking the fat cell to insulin sensitivity. Lancet. 2003, 362 (9394): 1431-1432. 10.1016/S0140-6736(03)14727-7.CrossRefPubMed
5.
Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev. 2005, 26 (3): 439-451. 10.1210/er.2005-0005.CrossRefPubMed
6.
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000, 20 (6): 1595-1599. 10.1161/01.ATV.20.6.1595.CrossRefPubMed
7.
Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM: Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001, 288 (5): 1102-1107. 10.1006/bbrc.2001.5904.CrossRefPubMed
8.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999, 257 (1): 79-83. 10.1006/bbrc.1999.0255.CrossRefPubMed
9.
Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999, 100 (25): 2473-2476. 10.1161/01.CIR.100.25.2473.CrossRefPubMed
10.
Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004, 89 (6): 2548-2556. 10.1210/jc.2004-0395.CrossRefPubMed
11.
Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF: T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004, 101 (28): 10308-10313. 10.1073/pnas.0403382101.CrossRefPubMedPubMedCentral
12.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003, 348 (17): 1625-1638. 10.1056/NEJMoa021423.CrossRefPubMed
13.
Kolonel LN, Altshuler D, Henderson BE: The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer. 2004, 4 (7): 519-527. 10.1038/nrc1389.CrossRefPubMed
14.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008, 371 (9612): 569-578. 10.1016/S0140-6736(08)60269-X.CrossRefPubMed
15.
Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D: Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004, 89 (3): 1102-1107. 10.1210/jc.2003-031804.CrossRefPubMed
16.
Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C: Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004, 89 (3): 1160-1163. 10.1210/jc.2003-031716.CrossRefPubMed
17.
Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, Handy J, Page AJ, Cohen C, Anania FA, Saxena NK: Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010, 52 (5): 1713-1722. 10.1002/hep.23892.CrossRefPubMedPubMedCentral
18.
Perrier S, Jarde T: Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer. Curr Med Chem. 2012, 19 (32): 5501-5512. 10.2174/092986712803833137.CrossRefPubMed
19.
Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB: Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol. 2010, 24 (7): 1441-1452. 10.1210/me.2009-0498.CrossRefPubMed
20.
Ogunwobi OO, Beales IL: Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept. 2006, 134 (2–3): 105-113.CrossRefPubMed
21.
Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS: Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005, 97 (22): 1688-1694. 10.1093/jnci/dji376.CrossRefPubMed
22.
Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P: Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2006, 15 (2): 401-402. 10.1158/1055-9965.EPI-05-0836.CrossRefPubMed
23.
Yoneda K, Tomimoto A, Endo H, Iida H, Sugiyama M, Takahashi H, Mawatari H, Nozaki Y, Fujita K, Yoneda M, Inamori M, Nakajima N, Wada K, Nagashima Y, Nakagama H, Uozaki H, Fukayama M, Nakajima A: Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep. 2008, 20 (3): 479-483.PubMed
24.
Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, Tseleni-Balafouta S, Mantzoros CS: Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer. 2008, 15 (1): 289-299. 10.1677/ERC-07-0197.CrossRefPubMed
25.
Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, Dornan D: miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One. 2013, 8 (6): e66502-10.1371/journal.pone.0066502.CrossRefPubMedPubMedCentral
26.
World Health Organisation, International Association for the Study of Obesity, International Obesity Task Force: The Asia-Pacific Perspective Redefining obesity and its treatment. 2000, Health Communications
27.
Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, Xiao SD: Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis. 2011, 12 (4): 234-244. 10.1111/j.1751-2980.2011.00504.x.CrossRefPubMed
28.
Otake S, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, Saito T, Togashi H, Nakamura T, Matsuzawa Y, Kawata S: Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res. 2005, 11 (10): 3642-3646. 10.1158/1078-0432.CCR-04-1868.CrossRefPubMed
29.
Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S, Kawata S: Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol. 2010, 16 (10): 1252-1257. 10.3748/wjg.v16.i10.1252.CrossRefPubMedPubMedCentral
30.
Saltevo J, Vanhala M, Kautiainen H, Kumpusalo E, Laakso M: Gender differences in C-reactive protein, interleukin-1 receptor antagonist and adiponectin levels in the metabolic syndrome: a population-based study. Diabet Med. 2008, 25 (6): 747-750. 10.1111/j.1464-5491.2008.02440.x.CrossRefPubMed
31.
Adamczak M, Rzepka E, Chudek J, Wiȩcek A: Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol. 2005, 62 (1): 114-118. 10.1111/j.1365-2265.2004.02182.x.CrossRef
32.
Durand JL, Nawrocki AR, Scherer PE, Jelicks LA: Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase. J Cell Biochem. 2012, 29 (10): 24206-
33.
Lilja M, Rolandsson O, Norberg M, Soderberg S: The impact of leptin and adiponectin on incident type 2 diabetes is modified by sex and insulin resistance. Metab Syndr Relat Disord. 2012, 10 (2): 143-151. 10.1089/met.2011.0123.CrossRefPubMed
34.
Tabatabaei-Malazy O, Hasani-Ranjbar S, Amoli MM, Heshmat R, Sajadi M, Derakhshan R, Amiri P, Namakchian M, Rezazadeh E, Tavakkoly-Bazzaz J, Keshtkar A, Larijani B: Gender-specific differences in the association of adiponectin gene polymorphisms with body mass index. Rev Diabet Stud. 2010, 7 (3): 241-246.PubMedPubMedCentral
35.
Kern PA, Gregorio GBD, Lu T, Rassouli N, Ranganathan G: Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-a expression. Diabetes. 2003, 52: 1779-1785. 10.2337/diabetes.52.7.1779.CrossRefPubMed
36.
Wang Y, Lam KSL, Xu A: Adiponectin as a negative regulator in obesity-related mammary carcinogenesis. Cell Res. 2007, 17 (4): 280-282. 10.1038/cr.2007.14.CrossRefPubMed
37.
38.
Dalamaga M, Diakopoulos KN, Mantzoros CS: The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012, 33 (4): 547-594. 10.1210/er.2011-1015.CrossRefPubMedPubMedCentral
39.
Gialamas SP, Petridou ET, Tseleni-Balafouta S, Spyridopoulos TN, Matsoukis IL, Kondi-Pafiti A, Zografos G, Mantzoros CS: Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism. 2011, 60 (11): 1530-1538. 10.1016/j.metabol.2011.03.020.CrossRefPubMed
40.
Fenton JI, Birmingham JM: Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. Mol carcinog. 2010, 49 (7): 700-709.PubMedPubMedCentral
41.
Moon H-S, Liu X, Nagel JM, Chamberland JP, Diakopoulos KN, Brinkoetter MT, Hatziapostolou M, Wu Y, Robson SC, Iliopoulos D, Mantzoros CS: Salutary effects of adiponectin on colon cancer: in vivo and in vitro studies in mice. Gut. 2013, 62 (4): 561-570. 10.1136/gutjnl-2012-302092.CrossRefPubMed
42.
Byeon JS, Jeong JY, Kim MJ, Lee SM, Nam WH, Myung SJ, Kim JG, Yang SK, Kim JH, Suh DJ: Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer. 2010, 127 (12): 2758-2767. 10.1002/ijc.25301.CrossRefPubMed
43.
Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M, Nakajima N, Watanabe M, Kubota N, Yamauchi T, Kadowaki T, Wada K, Nakagama H, Nakajima A: Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut. 2008, 57 (11): 1531-1538. 10.1136/gut.2008.159293.CrossRefPubMedPubMedCentral
44.
Mifflin RC, Pinchuk IV, Saada JI, Powell DW: Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol. 2011, 300: G684-G696.
45.
Konstantinopoulos PA, Vandoros GP, Karamouzis MV, Gkermpesi M, Sotiropoulou-Bonikou G, Papavassiliou AG: EGF-R is expressed and AP-1 and NF-κB are activated in stromal myofibroblasts surrounding colon adenocarcinomas paralleling expression of COX-2 and VEGF. Anal Cell Pathol. 2007, 29 (6): 477-482.
46.
Alexis D, Christelle G, Giulio G: The stroma reaction myofibroblast: a key player in the control of tumor cell behavior. Int J Dev Biol. 2004, 48: 509-517. 10.1387/ijdb.041802ad.CrossRef
47.
Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E: Epithelial-mesenchymal transition. Cancer Res. 2008, 68 (23): 9574-9577. 10.1158/0008-5472.CAN-08-2316.CrossRefPubMed
48.
Takeuchi T, Adachi Y, Ohtsuki Y, Furihata M: Adiponectin receptors, with special focus on the role of the third receptor, T-cadherin, in vascular disease. Med Mol Morphol. 2007, 40 (3): 115-120. 10.1007/s00795-007-0364-9.CrossRefPubMed
49.
Berx G, van Roy F: Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor Perspect Biol. 2009, 1: 6-CrossRef
50.
J-z R, J-r H: Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells. Med Oncol. 2012, 29 (2): 915-918. 10.1007/s12032-011-9836-9.CrossRef
51.
Hwang J-T, Ha J, Park I-J, Lee S-K, Baik HW, Kim YM, Park OJ: Apoptotic effect of EGCG in HT-29 colon cancer cells via AMPK signal pathway. Cancer Lett. 2007, 247 (1): 115-121. 10.1016/j.canlet.2006.03.030.CrossRefPubMed
52.
Vetvik KK, Sonerud T, Lindeberg M, Luders T, Storkson RH, Jonsdottir K, Frengen E, Pietilainen KH, Bukholm I: Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in vitro studies. Metabolism. 2014, 63 (5): 672-681. 10.1016/j.metabol.2014.02.001.CrossRefPubMed
Metadata
Title
Involvement of adiponectin in early stage of colorectal carcinogenesis
Authors
Chung Hyun Tae
Seong-Eun Kim
Sung-Ae Jung
Yang-Hee Joo
Ki-Nam Shim
Hye-Kyung Jung
Tae Hun Kim
Min-Sun Cho
Kwang Ho Kim
Joung Sook Kim
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-811

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Glucose-regulated protein 58 modulates β-catenin protein stability in a cervical adenocarcinoma cell line

Research article

MicroRNA profile in very young women with breast cancer

Research article

In vitro evaluation of novel N-acetylalaninate prodrugs that selectively induce apoptosis in prostate cancer cells

Research article

Genomic profile of ovarian carcinomas

Research article

Tumor cells with low proteasome subunit expression predict overall survival in head and neck cancer patients

Research article

Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits